The firm studied its ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.
Transpharma Medical Ltd. has successfully completed a Phase I clinical trial (safety)of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain. The company has developed proprietary active transdermal drug delivery system to replace injections.
Transpharma said that the trial results showed the possibility of expanding the use of Calcitonin for new treatments beyond its current ones.
Transpharma is also jointly developing a product for the treatment of osteoporosis with Eli Lilly Co. (NYSE: LLY). This product is undergoing a Phase IIb clinical trial. Transpharma is also independently developing a third product, a growth hormone, which has completed a Phase I clinical trial.
Published by Globes [online], Israel business news - www.globes-online.com - on January 12, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011